title: Burkitt's and Burkitt-like lymphoma in children and adolescents: a review of the Children's Cancer Group experience.
abstract: Historically, the survival of children and adolescents with Burkitt's and Burkitt-like lymphoma had been poor. Recently, short and intensive chemotherapy appears to have improved disease outcome. We therefore reviewed the results of four successive Children's Cancer Group trials conducted on 470 children with disseminated Burkitt's and Burkitt-like lymphoma. Of the patients studied, the median age was 8 years (0-21 years), the male:female ratio was 4:1, 58% had lactate dehydrogenase (LDH) > or = 500 IU/l, 23% had M2 or M3 bone marrow (BM), and 12% demonstrated central nervous system involvement. In a multivariate analysis, the 4-year event-free survival (EFS) in patients > or = 15-years-old compared with < 15-year-old was 34 +/- 7 versus 59 +/- 2% (P < 0.05), the 4-year EFS of M2/M3 compared with M1 BM was 38 +/- 5 versus 63 +/- 3% (P < 0.001), and the 4-year EFS with LDH > or = 500 IU/l compared with LDH < 500 IU/l was 49 +/- 3 versus 71 +/- 4% (P < 0.001). Furthermore, patients treated on the most recent protocol, which was short and more intensive, had a significantly improved survival compared with those on previous trials (4-year EFS 80 +/- 6 versus 54 +/- 2%, P < 0.001). In summary, the outcome for childhood Burkitt's and Burkitt-like lymphoma has recently improved with the use of short and intensive B-cell non-Hodgkin's lymphoma-directed therapy.
authors.affiliation: Department of Pediatrics, Children's Hospital New York, Columbia University, New York, NY, USA. mc1310@columbia.edu
authors.forename: Mitchell S
authors.initials: MS
authors.lastname: Cairo
authors.forename: Richard
authors.initials: R
authors.lastname: Sposto
authors.forename: Sherrie L
authors.initials: SL
authors.lastname: Perkins
authors.forename: Anna T
authors.initials: AT
authors.lastname: Meadows
authors.forename: Margo L
authors.initials: ML
authors.lastname: Hoover-Regan
authors.forename: James R
authors.initials: JR
authors.lastname: Anderson
authors.forename: Stuart E
authors.initials: SE
authors.lastname: Siegel
authors.forename: Mark A
authors.initials: MA
authors.lastname: Lones
authors.forename: Nicole
authors.initials: N
authors.lastname: Tedeschi-Blok
authors.forename: Marshall E
authors.initials: ME
authors.lastname: Kadin
authors.forename: Carl R
authors.initials: CR
authors.lastname: Kjeldsberg
authors.forename: John F
authors.initials: JF
authors.lastname: Wilson
authors.forename: Warren
authors.initials: W
authors.lastname: Sanger
authors.forename: Erin
authors.initials: E
authors.lastname: Morris
authors.forename: Mark D
authors.initials: MD
authors.lastname: Krailo
authors.forename: Jonathan L
authors.initials: JL
authors.lastname: Finlay
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism; D001853:Bone Marrow / Q000473:pathology; D002051:Burkitt Lymphoma / Q000188:drug therapy* / Q000201:enzymology; D002490:Central Nervous System / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D008297:Male; D015999:Multivariate Analysis; D011379:Prognosis; D016016:Proportional Hazards Models; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D007770:L-Lactate Dehydrogenase